Dr. Reddy's Laboratories Limited
NSE: DRREDDY BSE: DRREDDY
NSE
1,258.80
9.50 (0.76%)
Prev Close
1249.3
Open Price
1250
Volume
809,672
Today Low / High
1245 / 1260.3
52 WK Low / High
1020 / 1405.9
Range
1,196 - 1,322
BSE
1,258.15
7.65 (0.61%)
Prev Close
1250.5
Open Price
1250
Volume
43,484
Today Low / High
1245 / 1260
52 WK Low / High
1025.9 / 1404.6
Range
1,195 - 1,321
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1258.8 (target range: 1,196 - 1,322), reflecting a change of 9.5 (0.76043%). On the BSE, it is listed at 1258.15 (target range: 1,195 - 1,321), showing a change of 7.65 (0.61176%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
28 Nov
1,250.00
0.70%
27 Nov
1,248.00
0.10%
26 Nov
1,236.10
0.96%
25 Nov
1,236.30
-0.02%
24 Nov
1,248.00
-1.75%
21 Nov
1,244.80
-0.07%
19 Nov
1,248.70
0.12%
18 Nov
1,244.50
-0.06%
17 Nov
1,253.00
-0.69%
14 Nov
1,235.20
0.87%
13 Nov
1,235.80
-0.07%
12 Nov
1,220.10
0.78%
11 Nov
1,203.60
0.66%
10 Nov
1,199.40
-0.06%
07 Nov
1,208.00
-0.22%
06 Nov
1,202.00
0.27%
04 Nov
1,198.00
0.17%
03 Nov
1,196.90
-0.08%
31 Oct
1,202.50
-0.41%
Dr. Reddy's Laboratories Limited Graph
Dr. Reddy's Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Dr. Reddy's Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,258.80, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,258.15 | 1,270.73 | 1,143.66 - 1,397.80 |
| 1,283.31 | 1,026.65 - 1,539.98 | ||
| 1,295.89 | 907.13 - 1,684.66 | ||
| Bearish Scenario | 1,258.15 | 1,245.57 | 1,121.01 - 1,370.13 |
| 1,232.99 | 986.39 - 1,479.58 | ||
| 1,220.41 | 854.28 - 1,586.53 |
Overview of Dr. Reddy's Laboratories Limited
ISIN
INE089A01031
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
1,800,056
Market Cap
1,047,966,766,470
Last Dividend
8
Official Website
IPO Date
1996-01-01
DCF Diff
-1,417.70
DCF
2,676
Financial Ratios Every Investor Needs
Stock Dividend of DRREDDY
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-10 | July 10, 25 | 8 | 8 | 2025-07-10 | 2025-08-23 | |
| 2024-07-16 | July 16, 24 | 691.056 | 3455.28 | 2024-07-16 | 2024-08-28 | |
| 2023-07-11 | July 11, 23 | 8 | 40 | 2023-07-11 | 2023-08-26 | |
| 2022-07-11 | July 11, 22 | 6 | 30 | 2022-07-12 | 2022-08-28 | |
| 2021-07-09 | July 09, 21 | 5 | 25 | 2021-07-12 | 2021-08-27 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 32,553.50 Cr | 13,510.70 Cr | 19,042.80 Cr | 0.5850 | 2,738.00 Cr | 0.00 Cr | 7,184.30 Cr | 5,654.40 Cr | 67.88 | 8,884.00 Cr | 0.1737 |
| 2024-03-31 | 27,916.40 Cr | 11,555.70 Cr | 16,360.70 Cr | 0.5861 | 2,287.30 Cr | 0.00 Cr | 6,772.90 Cr | 5,568.40 Cr | 66.93 | 7,928.60 Cr | 0.1995 |
| 2023-03-31 | 24,587.90 Cr | 10,653.60 Cr | 13,934.30 Cr | 0.5667 | 1,938.10 Cr | 0.00 Cr | 5,714.40 Cr | 4,506.70 Cr | 54.29 | 6,605.20 Cr | 0.1833 |
| 2022-03-31 | 21,439.10 Cr | 10,055.10 Cr | 11,384.00 Cr | 0.5310 | 1,748.20 Cr | 0.00 Cr | 2,947.60 Cr | 2,356.80 Cr | 28.42 | 4,774.30 Cr | 0.1099 |
| 2021-03-31 | 18,972.20 Cr | 8,664.50 Cr | 10,307.70 Cr | 0.5433 | 1,654.10 Cr | 0.00 Cr | 2,428.00 Cr | 1,723.80 Cr | 20.79 | 4,570.60 Cr | 0.0909 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,465.40 Cr | 49,298.90 Cr | 15,582.30 Cr | 33,338.8000 Cr | 4,676.60 Cr | 3,211.20 Cr | 7,108.50 Cr | 9,776.10 Cr | 0.00 Cr | 116.20 Cr | 1,520.20 Cr | 13,039.2000 Cr |
| 2024-03-31 | 710.70 Cr | 38,751.80 Cr | 10,696.80 Cr | 28,055.0000 Cr | 2,002.00 Cr | 1,291.30 Cr | 6,355.20 Cr | 7,688.60 Cr | 143.50 Cr | 119.30 Cr | 525.50 Cr | 9,603.9000 Cr |
| 2023-03-31 | 577.90 Cr | 32,285.10 Cr | 8,999.00 Cr | 23,099.1000 Cr | 1,347.20 Cr | 769.30 Cr | 4,867.00 Cr | 5,654.20 Cr | 198.10 Cr | 155.50 Cr | 536.20 Cr | 8,572.1000 Cr |
| 2022-03-31 | 1,485.20 Cr | 29,665.40 Cr | 10,612.70 Cr | 19,052.7000 Cr | 3,384.50 Cr | 1,899.30 Cr | 5,088.40 Cr | 6,216.90 Cr | 257.60 Cr | 159.70 Cr | 798.60 Cr | 9,401.5000 Cr |
| 2021-03-31 | 1,482.90 Cr | 26,549.10 Cr | 9,051.00 Cr | 17,306.2000 Cr | 3,030.80 Cr | 1,547.90 Cr | 4,541.20 Cr | 5,711.10 Cr | 203.30 Cr | 153.10 Cr | 833.30 Cr | 8,339.1000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4,642.8000 Cr | -5,102.1000 Cr | 1,185.5000 Cr | 1,892.4000 Cr | 748.6000 Cr | 1,459.3000 Cr | -2,750.4000 Cr | 5,654.4000 Cr | -129.4000 Cr | -666.2000 Cr | -1,275.3000 Cr |
| 2024-03-31 | 4,543.3000 Cr | -4,028.3000 Cr | -376.3000 Cr | 1,799.8000 Cr | 132.8000 Cr | 710.7000 Cr | -2,743.5000 Cr | 5,568.4000 Cr | 434.6000 Cr | -664.8000 Cr | -1,844.5000 Cr |
| 2023-03-31 | 5,887.3000 Cr | -4,137.1000 Cr | -2,686.1000 Cr | 4,000.9000 Cr | -907.3000 Cr | 577.9000 Cr | -1,886.4000 Cr | 6,048.5000 Cr | -2,039.7000 Cr | -497.9000 Cr | -265.4000 Cr |
| 2022-03-31 | 2,810.8000 Cr | -2,638.7000 Cr | -242.2000 Cr | 905.9000 Cr | 3.2000 Cr | 1,485.2000 Cr | -1,904.9000 Cr | 2,356.8000 Cr | 273.5000 Cr | -414.6000 Cr | -532.8000 Cr |
| 2021-03-31 | 3,570.3000 Cr | -2,266.0000 Cr | -29.8000 Cr | 2,314.2000 Cr | 1,285.8000 Cr | 1,482.0000 Cr | -1,256.1000 Cr | 1,914.9000 Cr | 609.4000 Cr | -414.7000 Cr | -988.1000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 8,805.10 Cr | 3,991.10 Cr | 4,814.00 Cr | 0.5467 | 1,751.30 Cr | 1,437.20 Cr | 17.22 | 2,430.80 Cr | 0.1632 |
| 2025-06-30 | 8,545.20 Cr | 3,682.50 Cr | 4,862.70 Cr | 0.5691 | 1,747.50 Cr | 1,417.80 Cr | 17.04 | 2,228.00 Cr | 0.1659 |
| 2025-03-31 | 8,506.00 Cr | 3,779.70 Cr | 4,726.30 Cr | 0.5556 | 1,764.70 Cr | 1,593.80 Cr | 19.13 | 2,065.30 Cr | 0.1874 |
| 2024-12-31 | 8,358.60 Cr | 3,453.40 Cr | 4,905.20 Cr | 0.5868 | 1,872.00 Cr | 1,413.30 Cr | 16.96 | 2,342.70 Cr | 0.1691 |
| 2024-09-30 | 8,016.20 Cr | 3,239.30 Cr | 4,776.90 Cr | 0.5959 | 1,755.10 Cr | 1,255.30 Cr | 15.07 | 2,202.00 Cr | 0.1566 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 990.60 Cr | 5,990.50 Cr | 6,981.10 Cr | 12,084.10 Cr | 7,582.10 Cr | 27,951.70 Cr | 11,198.10 Cr | 54,200.50 Cr | 17,992.30 Cr |
| 2025-06-30 | 900.40 Cr | 5,768.40 Cr | 6,668.80 Cr | 11,544.30 Cr | 7,560.00 Cr | 26,989.80 Cr | 10,278.40 Cr | 51,953.70 Cr | 16,578.20 Cr |
| 2025-03-31 | 1,465.40 Cr | 4,325.40 Cr | 5,790.80 Cr | 9,042.00 Cr | 7,108.50 Cr | 25,011.20 Cr | 9,776.10 Cr | 49,298.90 Cr | 15,582.30 Cr |
| 2024-12-31 | 1,228.90 Cr | 4,689.00 Cr | 5,917.90 Cr | 11,149.40 Cr | 7,163.00 Cr | 25,301.60 Cr | 9,305.30 Cr | 48,105.90 Cr | 15,949.40 Cr |
| 2024-09-30 | 1,133.00 Cr | 5,174.40 Cr | 6,307.40 Cr | 9,190.30 Cr | 7,203.90 Cr | 24,812.80 Cr | 8,669.30 Cr | 46,595.50 Cr | 15,667.20 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 1,426.80 Cr | 1,557.30 Cr | -954.30 Cr | -532.30 Cr | 90.20 Cr | 990.60 Cr | 900.40 Cr | -1,013.50 Cr | 543.80 Cr |
| 2025-06-30 | 1,409.60 Cr | 1,462.90 Cr | -1,919.20 Cr | -120.30 Cr | -558.90 Cr | 900.40 Cr | 1,459.30 Cr | -1,014.70 Cr | 448.20 Cr |
| 2025-03-31 | 1,593.90 Cr | 2,199.60 Cr | -624.40 Cr | -1,442.60 Cr | 156.10 Cr | 1,459.30 Cr | 1,303.20 Cr | -766.20 Cr | 1,433.40 Cr |
| 2024-12-31 | 1,403.80 Cr | 662.00 Cr | -545.80 Cr | 59.00 Cr | 174.70 Cr | 1,303.20 Cr | 1,128.50 Cr | -881.90 Cr | -219.90 Cr |
| 2024-09-30 | 1,255.30 Cr | 931.60 Cr | -1,907.10 Cr | 1,615.00 Cr | 637.20 Cr | 1,128.50 Cr | 491.30 Cr | -790.90 Cr | 140.70 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2024-10-28 | October 28, 24 | 5:1 |
| 2006-08-28 | August 28, 06 | 2:1 |
| 2001-10-10 | October 10, 01 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,831.60 | ₹4,394,621,931,052.00 | ₹1,623,022.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,477.00 | ₹1,719,439,992,660.00 | ₹250,077.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,720.60 | ₹1,259,220,104,064.00 | ₹164,885.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,258.80 | ₹1,047,966,766,470.00 | ₹809,672.00 |
| Lupin Limited | LUPIN | ₹2,082.20 | ₹951,070,211,196.00 | ₹822,530.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹942.50 | ₹948,375,535,575.00 | ₹919,925.00 |
| Mankind Pharma Limited | MANKIND | ₹2,251.00 | ₹929,119,338,480.00 | ₹267,027.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,226.70 | ₹712,469,350,934.00 | ₹556,060.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,685.00 | ₹679,727,025,000.00 | ₹57,067.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,031.35 | ₹556,748,409,584.00 | ₹2,485,745.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,946.20 | ₹549,219,214,476.00 | ₹687,380.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,453.10 | ₹368,657,599,176.00 | ₹454,293.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,560.80 | ₹319,935,145,939.00 | ₹42,956.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,771.30 | ₹277,433,405,100.00 | ₹81,652.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,414.30 | ₹268,101,563,112.00 | ₹142,264.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,024.00 | ₹225,600,000,000.00 | ₹5,257.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹17,288.00 | ₹221,803,121,032.00 | ₹91,639.00 |
| Eris Lifesciences Limited | ERIS | ₹1,595.40 | ₹217,315,815,600.00 | ₹35,120.00 |
| Cohance Lifesciences Limited | COHANCE | ₹564.40 | ₹215,920,893,816.00 | ₹280,403.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,235.00 | ₹200,677,828,715.00 | ₹445,453.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹907.20 | ₹178,322,066,093.00 | ₹42,097.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,089.70 | ₹172,715,744,620.00 | ₹68,403.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹877.25 | ₹157,124,133,458.00 | ₹2,142,653.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,910.80 | ₹145,243,148,717.00 | ₹25,901.00 |
| Granules India Limited | GRANULES | ₹556.10 | ₹134,948,072,968.00 | ₹855,733.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹898.50 | ₹110,229,191,178.00 | ₹29,654.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,722.50 | ₹94,989,963,495.00 | ₹5,333.00 |
| Strides Pharma Science Limited | STAR | ₹878.40 | ₹80,964,511,978.00 | ₹133,318.00 |
| FDC Limited | FDC | ₹414.40 | ₹67,468,498,810.00 | ₹39,675.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹341.50 | ₹66,791,190,164.00 | ₹181,647.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹425.95 | ₹65,213,821,605.00 | ₹158,674.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹700.65 | ₹63,512,026,541.00 | ₹202,623.00 |
| Sequent Scientific Limited | SEQUENT | ₹223.46 | ₹55,825,630,594.00 | ₹1,211,340.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹407.60 | ₹44,414,242,014.00 | ₹87,401.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹134.51 | ₹43,651,398,802.00 | ₹221,821.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹833.20 | ₹42,259,158,286.00 | ₹126,882.00 |
| Innova Captab Limited | INNOVACAP | ₹718.25 | ₹41,101,805,254.00 | ₹9,801.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹424.85 | ₹38,776,059,500.00 | ₹113,216.00 |
| Suven Life Sciences Limited | SUVEN | ₹172.14 | ₹37,940,691,422.00 | ₹118,201.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,278.10 | ₹37,677,530,072.00 | ₹5,465.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹355.65 | ₹35,665,473,259.00 | ₹33,410.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹467.15 | ₹32,890,046,113.00 | ₹7,973.00 |
Key Executives
Chief Executive Officer of Branded Markets - India & Emerging Countries and Member of Management Council
Mr. Motupalli Venkata Ramana M.B.A.
Gender: male
Year Born: 1969
EVice President, Head of Corporate Communications, Chief Human Resources Officer & Member of Management Council
Ms. Archana Bhaskar B.Sc., M.B.A.
Gender: female
Year Born: 1967
Co-Chairman, MD & Member of Management Council
Mr. Gunupati Venkateswara Prasad B.E.
Gender: male
Year Born: 1960
Executive Vice President, Global Head of Global Manufacturing & Member of Management Council
Mr. Sanjay Sharma B.Tech.
Gender: male
Year Born: 1968
Head of Generics, Europe & Consumer Health and Member of Management Council
Mr. Patrick Aghanian B.A., M.B.A.
Gender: male
Year Born: 1965
Global Head of Quality and Pharmacovigilance & Member of the Management Council
Mr. Krishna K. Venkatesh B.Pharma M.S.
Gender: male
Year Born: 1973
Chairman of the Board & Member of the Management Council
Mr. Kallam Satish Reddy B.Tech., M.S.
Gender: male
Year Born: 1967
Chief Financial Officer & Member of the Management Council
Mr. Mannam Venkatanarasimham
Gender: male
Year Born: 1969
Global Head of Pharmaceutical Services and Active Ingredients & Member of Management Council
Mr. Deepak Sapra M.B.A.
Gender: male
Year Born: 1975
Chief Executive Officer & Member of the Management Council
Mr. Erez Israeli M.B.A.
Gender: male
Year Born: 1968
FAQs about Dr. Reddy's Laboratories Limited
Who is the CEO of the company?
The CEO is Erez Israeli.
What is the current market price of the stock?
The current price is ₹1,258.80.
What is the 52-week price range?
The range is ₹1020-1405.9.
What is the market capitalization of the company?
The market capitalization is ₹104,796.68 crores.
What is the dividend yield?
The dividend yield is 0.64%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 17.92.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Dr. Reddy's Laboratories Limited (ISIN: INE089A01031) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹104,796.68 crores and an average daily volume of 1,800,056 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹8.